Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637893 | 0.92 | ALDH1A1 (0.42) | ALDH1A1HPGDHSD17B10RCE1ELANE | |
| SCHEMBL544091 | 0.86 | ALDH1A1 (0.43) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL640695 | 0.83 | ALDH1A1 (0.44) | ALDH1A1HPGDHSD17B10RCE1GSK3A | |
| SCHEMBL543420 | 0.82 | ALDH1A1 (0.40) | ALDH1A1HPGDHSD17B10ELANE | |
| SCHEMBL544393 | 0.82 | ALDH1A1 (0.43) | ALDH1A1HPGDHSD17B10KDM4EGAA | |
| SCHEMBL544337 | 0.82 | ALDH1A1 (0.43) | ALDH1A1HPGDHSD17B10RCE1KDM4E | |
| SCHEMBL543866 | 0.79 | ALDH1A1 (0.42) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL15803165 | 0.79 | ALDH1A1 (0.40) | ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL543720 | 0.78 | ALDH1A1 (0.44) | ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL543569 | 0.78 | ALDH1A1 (0.41) | ALDH1A1HPGDHSD17B10RCE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388002-B1 | Antidepressant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2013-03-13 | — | — | EP | claimed |
| EP-2388002-A2 | Antidepressant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-11-23 | — | — | EP | claimed |
| US-8040824-B2 | Methods and apparatus for content delivery via application level multicast with minimum communication delay | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-10-18 | — | — | US | claimed |
| US-20110059998-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | ZENYAKU KOGYO KABUSHIKI KAISHA | 2011-03-10 | — | — | US | claimed |
| EP-2257290-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2010-12-08 | — | — | EP | claimed |
| WO-2009107401-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2009-09-03 | — | — | WO | claimed |
| US-20090221554-A1 | METHOD OF TREATING COGNITIVE IMPAIRMENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2009-09-03 | — | — | US | claimed |
| EP-2077836-A2 | ANTIDEPRESSANT, NEUROPROTECTANT, AMYLOID BETA DEPOSITION INHIBITOR OR AGE RETARDANT CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2009-07-15 | — | — | EP | claimed |
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | claimed |
| WO-2008047952-A2 | ANTIDEPRESSANT, NEUROPROTECTANT, AMYLOID BETA DEPOSITION INHIBITOR OR AGE RETARDANT CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | claimed |
| EP-2388000-B1 | Neuroprotectant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2388000-B1 | Neuroprotectant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2077836-B1 | AMYLOID BETA DEPOSITION INHIBITOR CONTAINING SPIRO-HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KK (JP) | 2016-03-09 | — | — | EP | disclosed |
| EP-2077836-B1 | AMYLOID BETA DEPOSITION INHIBITOR CONTAINING SPIRO-HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KK (JP) | 2016-03-09 | — | — | EP | disclosed |
| EP-2388001-B1 | Age retardant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2015-12-16 | — | — | EP | disclosed |
| WO-2008047952-A2 | ANTIDEPRESSANT, NEUROPROTECTANT, AMYLOID BETA DEPOSITION INHIBITOR OR AGE RETARDANT CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047951-A2 | AN ALZHEIMER' S DISEASE PROGRESSION INHIBITOR CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | disclosed |
| EP-1219621-B1 | AZAINDOLIZINONE DERIVATIVES AND COGNITIVE ENHANCERS COMPRISING THE SAME AS EFFECTIVE COMPONENTS | ZENYAKU KOGYO KK (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6635652-B1 | Senile dementia and Alzheimer's disease | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2003-10-21 | — | — | US | disclosed |
| EP-1219621-A1 | AZAINDOLIZINONE DERIVATIVES AND CEREBRAL FUNCTION IMPROVERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | PSEN1, PSEN2, BDNF | ALDH1A1 159/4885HPGD 570/4885HSD17B10 761/4885 |
| US-20110059998-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | KIT, CHAT, BDNF | ALDH1A1 1567/4885HPGD 1443/4885HSD17B10 2360/4885 |
| US-20090221554-A1 | METHOD OF TREATING COGNITIVE IMPAIRMENT | CHAT, ACHE, BCHE | ALDH1A1 1056/4885HPGD 253/4885HSD17B10 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.